- Home
- EWTX vs DXPE Comparison
EWTX vs DXPE Comparison
Compare EWTX & DXPE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWTX
- DXPE
- Stock Information
- Founded
- EWTX 2017
- DXPE 1908
- Country
- EWTX United States
- DXPE United States
- Employees
- EWTX N/A
- DXPE N/A
- Industry
- EWTX Biotechnology: Pharmaceutical Preparations
- DXPE Industrial Machinery/Components
- Sector
- EWTX Health Care
- DXPE Industrials
- Exchange
- EWTX Nasdaq
- DXPE Nasdaq
- Market Cap
- EWTX 1.2B
- DXPE 1.4B
- IPO Year
- EWTX 2021
- DXPE 1996
- Fundamental
- Price
- EWTX $14.28
- DXPE $82.68
- Analyst Decision
- EWTX Buy
- DXPE Buy
- Analyst Count
- EWTX 8
- DXPE 1
- Target Price
- EWTX $40.13
- DXPE $95.00
- AVG Volume (30 Days)
- EWTX 1.1M
- DXPE 95.9K
- Earning Date
- EWTX 05-08-2025
- DXPE 05-07-2025
- Dividend Yield
- EWTX N/A
- DXPE N/A
- EPS Growth
- EWTX N/A
- DXPE 33.22
- EPS
- EWTX N/A
- DXPE 4.81
- Revenue
- EWTX N/A
- DXPE $1,865,974,000.00
- Revenue This Year
- EWTX N/A
- DXPE $11.87
- Revenue Next Year
- EWTX N/A
- DXPE $3.57
- P/E Ratio
- EWTX N/A
- DXPE $17.20
- Revenue Growth
- EWTX N/A
- DXPE 11.94
- 52 Week Low
- EWTX $10.60
- DXPE $43.25
- 52 Week High
- EWTX $38.12
- DXPE $107.06
- Technical
- Relative Strength Index (RSI)
- EWTX 43.22
- DXPE 41.91
- Support Level
- EWTX $13.80
- DXPE $81.67
- Resistance Level
- EWTX $14.68
- DXPE $86.35
- Average True Range (ATR)
- EWTX 0.78
- DXPE 2.86
- MACD
- EWTX 0.08
- DXPE -0.80
- Stochastic Oscillator
- EWTX 29.68
- DXPE 14.81
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
About DXPE DXP Enterprises Inc.
DXP Enterprises Inc is a distributor of products and services to industrial customers in the United States, Canada, Mexico, and Dubai. The company's reportable segments include Service Centers, Innovative Pumping Solutions, and Supply Chain Services. It generates maximum revenue from the Service Centers segment. The company offers pumping solutions, supply chain services and maintenance, repair, operating, and production services for rotating equipment, bearings, power transmissions, industrial supplies, and safety products. It serves the General Industrial, Oil & Gas, Food & Beverage, Water & Wastewater, Chemical, Transportation, Aerospace & Others.